Trial Profile

A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Dose, 2-Period Crossover Study to Evaluate the Pharmacodynamics of RM-131 Administered to Patients With Diabetic Gastroparesis.

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 29 Sep 2016

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Relamorelin (Primary)
Indications Diabetic gastroparesis
Focus Pharmacodynamics; Therapeutic Use
Sponsors Rhythm

Most Recent Events

20 May 2013 Results from the type 1 diabetic cohort were presented at the Digestive Disease Week 2013 conference and published in Clinical Gastroenterology and Hepatology, according to a Rhythm Pharmaceuticals media release.
06 Sep 2012 Primary endpoint gastric emptying half-time for solids has been met.
22 May 2012 Status changed from recruiting to completed, based on information from a Rhythm Pharmaceuticals media release.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com